Introduction: Rotational total skin electron irradiation (RTSEI) is an effective therapy for
INTRODUCTION
Cutaneous T cell lymphoma (CTCL) is a rare group of lymphoproliferative disorders characterized by localization of T lymphocytes to the skin with an overall incidence of 10.2 cases per million person-years [1] . It is becoming increasingly recognized that CTCL is heterogeneous, with multiple variants that have unique clinical presentations, histologic features, and therapeutic considerations [2] . The most common subtype of CTCL is mycosis fungoides (MF), which typically presents with pruritic patches and plaques in areas of skin not commonly exposed to sun, and may evolve to cutaneous tumors or erythroderma [3] . Demographic features including African-American race, male gender, and age have been found to be risk factors for CTCL, while extent of skin involvement, overall disease stage, and age are prognostic indicators [2, 3] . The prognostic significance of lymphocytic CD30 positivity in CTCL prognosis remains controversial: some have reported it as a favorable prognostic factor, [4] while others have shown it to be associated with advanced disease and independently associated with poorer survival [5] .
Total skin electron irradiation (TSEI) has been shown to be an effective palliative treatment for CTCL, even following failure with previous treatment modalities. This has been demonstrated in multiple retrospective reviews showing that conventional dose dual-field irradiation (providing a theoretical advantage in dose homogeneity compared to its large-field/modified Stanford counterpart), showed promising results [12, 13] . Given that there have been no previous studies that have examined the response of CD30? CTCL to RTSEI, we investigated the effect of CD30 status on treatment response and survival in our cohort of patients with CTCL treated with conventional dose RTSEI.
METHODS

Patient Population
After institutional review board (IRB) approval was obtained from Emory University for this study, we retrospectively reviewed medical records of patients treated with RTSEI identified from billing records. RFS was calculated as the number of days between start of RTSEI and the date of recurrence. In the case of patients who did not have recurrence, RFS was censored at the date of last follow-up or date of death. OS was the number of days between diagnosis and the date of death or last known follow-up. RFS and OS distributions were estimated using the Kaplan-Meier method. Both RFS and OS were compared across race, T stage, and previously mentioned covariates, using log-rank tests and Cox proportional hazards models. Multivariate Cox models were fit, adjusting for T stage pre-TSEI, and the proportional hazards assumption was checked for all models. The cutoff for statistical significance for all analyses was set at the two-sided alpha error of 0.05. All analysis was done in SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient Characteristics
Medical records of 110 patients treated with RTSEI identified from billing records were retrospectively reviewed. After excluding 42 patients who either had a primary diagnosis of leukemia cutis or did not complete conventional dose RTSEI, 68 eligible patients remained. Individual case summaries of all CD30? patients are shown in Table 1 . Patient characteristics of the study cohort, stratified by CD30 status, are summarized in Table 2 . Sixty-eight patients were treated with conventional dose RTSEI (range 30-36 Gy). Median age at time of diagnosis was 51 years. patients, 7 (54%) were female and 6 were male (46%), and 7 were AA (54%) and 6 were white (46%). CD30? patients had a significantly more advanced T stage disease prior to RTSEI (62% T3, 39% T4) compared to CD30-patients (33% T2, 53% T3, 15% T4; Table 2 ). There were no significant differences between CD30 subgroups in regard to sex, race, age at diagnosis, time from diagnosis to RTSEI, treatments prior to RTSEI, maintenance therapy, follow-up time, or proportion that recurred after RTSEI. Table 3 summarizes CCR rates by CD30 status. CD30? patients had overall CCR rates of 85% at end of RTSEI, 85% at 6 weeks follow-up, 23% at 6 months follow-up. CD30-patients had overall CCR rates of 95% at the end of RTSEI, 79% at 6 weeks follow-up, and 50% at 6 months follow-up. Chi-square and Fisher's exact tests revealed no significant differences in CCR rate between CD30 status subgroups following end of RTSEI (P = 0.24) or six weeks (P = 0.44), but did trend toward significance at 6 months post-TSEI (P = 0.083). This trend was driven by a significantly poorer response at 6 months for CD30? T3 disease compared to CD30-T3 patients (P = 0.04). Further comparisons between CD30 status groups across respective CTCL cutaneous T cell lymphoma, RTSEI rotational total skin electron irradiation Bold P values are statistically significant (P \ 0.05) Bold P values are statistically significant (P \ 0.05)
Clinical Response Rates
T stages at all other follow-up time points showed no significance difference in CCR rates.
Relapse-Free Survival
As seen in Table 4 
Overall Survival
As seen in Table 4 On univariate analysis, CD30 status was not associated with OS (P = 0.57). In the CD30? group, non-MF histology (compared to MF histology) was associated with poorer OS in univariate analysis (HR = 10.65; P = 0.025).
However, after controlling for T stage pre-RTSEI, this observed effect only trended towards significance (P = 0.080). In the CD30-group, lower T stage (HR = 0.26; P = 0.049) in univariate analysis was associated with OS overall survival, RFS relapse-free survival, RTSEI rotational total skin electron irradiation improved OS. In multivariate analysis, increased time from diagnosis to RTSEI (HR = 0.98, P = 0.017) and younger age at RTSEI (HR = 1.06; P = 0.003) were associated with a significantly improved OS. Maintenance therapy failed to show any significant improvement in OS in both CD30?
(P = 0.998) and CD30-(P = 0.242) in multivariate analysis controlling for T stage pre-RTSEI. predominance of CD30 in the epidermis rather than dermis was associated with poorer survival [19] . However, a retrospective analysis of 100 patients with transformed MF from the Netherlands showed that CD30 negativity was associated with multivariate analysis with reduced disease-specific survival (DSS) and OS [4] . In a long-term outcomes study, CD30 was found to have no significant effect on OS, DSS, and progression-free survival (PFS) in 1263 MF SS patients at MDACC [17] . The CLIC reported that when CD30 is scored positive above 10% of tumoral cells, it is not statistically significant for OS but is associated with worse OS in the subset of patients with T3 disease [18] . [21] .
Based on the varying reports of the prognostic significance of CD30, we sought to assess the response and survival of our cohort of patients treated with RTSEI. We found 13 of 68 patients were CD30? (range 5% to 30%); they presented with significantly higher T stage at time of RTSEI and trended towards decreased CCR at 6 months post-RTSEI compared with the CD30-group. One patient in our cohort had 1% CD30? lymphocytes on pathology and was classified as negative for CD30; however, when this patient was added to the CD30? cohort (data not reported in results) the CCR was significantly reduced at 6 months (P = 0.05). 
